Abstract
Purpose
To investigate the efficacy of intravitreal bevacizumab for the treatment of idiopathic macular telangiectasia (IMT).
Methods
Ten eyes of eight consecutive patients with IMT were studied. Four eyes had type 1, and six had type 2 IMT according to Yannuzzi’s classification. All patients were treated with intravitreal bevacizumab (1.25 mg) injections at baseline. Monthly fundus and optical coherence tomography (OCT) examinations were performed. Changes in visual acuity, macular edema on OCT, and leakage on fluorescein angiography were analyzed during 6 months of follow-up. Retreatment was considered when increased macular edema and either fluorescein leakage or visual loss were identified.
Results
There were no changes in the mean visual acuity in either eye in any of the patients. In one of the four eyes with type 1 IMT, the microaneurysms disappeared after bevacizumab treatment. However, there were no changes in the other three eyes. Fluorescein leakage disappeared in four, decreased in one, and was unchanged in one of the eyes with type 2 IMT. An inner lamellar cyst in each eye was unchanged in two, newly formed in one, and expanded in one eye with type 2 IMT.
Conclusion
Type 2 IMT improved anatomically with bevacizumab treatment despite a lack of improvement in vision. Bevacizumab effectively decreases vascular permeability and retinal edema in the short term.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769–780.
Gass JDM, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis: update of classification and follow-up study. Ophthalmology 1993;100:1536–1546.
Yannuzzi LA, Bardal AMC, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthamol 2006;124:450–460.
Presta LG, Chen H, O’Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–4599.
Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69:11–16.
Kovach JL, Rosenfeld PJ. Bevacizumab (Avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009;29:27–32.
Charbel Issa P, Finger RP, Holtz FG, Scholl HP. Eighteen-months follow up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2007;92:941–945.
Moon SJ, Berger AS, Misch DM. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmol Surg Lasers Imaging 2007;38:164–166.
Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Ophthalmol 2008;246:1189–1193.
Park DW, Schatz H, McDonald HR, Johnson RN. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997;104:1838–1846.
Cakir M, Kapran Z, Basar D, Utine CA, Eroglu F, Perente I. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Euro J Ophthalmol 2006;16:711–717.
Eandi CM, Ober MD, Freund KB, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina 2006;26:780–785.
Jorge R, Costa RA, Calucci D, Scott IU. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Ophthalmol 2007;245:1045–1048.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Matsumoto, Y., Yuzawa, M. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 54, 320–324 (2010). https://doi.org/10.1007/s10384-010-0810-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-010-0810-4